MTHFR C677T heterozygous reduces 5,10-methylenetetrahydrofolate reductase activity by approximately 35%. This impairs conversion of folate to its active form, leading to elevated homocysteine and reduced methylation capacity. Affects DNA methylation, neurotransmitter synthesis, and glutathione production.

IL6 -174G>C promoter variant is associated with elevated IL-6 transcription in response to inflammatory stimuli. Patients with this variant show heightened systemic inflammatory response, increased NF-kB pathway sensitivity, and higher baseline CRP levels compared to wildtype.

CYP1B1 Leu432Val increases enzymatic activity toward estrogen catabolism, producing higher levels of 4-hydroxyestrogens — a reactive metabolite associated with oxidative DNA damage. Phase I detox pathway is affected; requires enhanced Phase II support to prevent downstream estrogen metabolite accumulation.

COMT Val158Met homozygous Met/Met genotype reduces catechol-O-methyltransferase activity by ~75%, significantly impairing dopamine and norepinephrine clearance in the prefrontal cortex. Results in heightened stress sensitivity, emotion dysregulation, pain amplification, and elevated catecholamine burden under stress conditions.

APOE ε4 heterozygous is associated with reduced LDL receptor function, impaired lipid clearance, and elevated cardiovascular risk. Also linked to mitochondrial dysfunction and increased neuroinflammatory sensitivity. The ε4 allele is a significant modifier for metabolic and neurological protocols.

VDR Bsm1 polymorphism is associated with modest reduction in vitamin D receptor expression, affecting calcium absorption, immune modulation, and tissue repair signaling. Clinical impact is generally low unless vitamin D levels are already suboptimal (<40 ng/mL).